Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has appointed Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, the company announced. The additions bring deep expertise in biotechnology, drug delivery, and central nervous system (CNS) clinical development, supporting Helus Pharma's pipeline of novel serotonergic agonists (NSAs) targeting major depressive disorder and generalized anxiety disorder.
Dr. Robert Langer is a renowned figure in biotechnology, holding over 1,400 issued or pending patents and having founded or co-founded numerous companies. His work in drug delivery systems has been pivotal in advancing controlled-release technologies. Dr. Stephen Brannan brings extensive experience in CNS clinical development, having led programs at multiple pharmaceutical companies. Their guidance will help Helus Pharma navigate the complexities of developing NSAs, which are synthetic molecules designed to activate serotonin pathways and promote neuroplasticity.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage company focused on addressing unmet needs in mental health. Its lead candidate, HLP003, is in Phase 3 development for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The appointments come as Helus Pharma emphasizes disciplined, evidence-based drug development. According to the company, the new advisory board members will provide strategic insights to advance its programs. For more details, the full press release is available at https://ibn.fm/CyjTq.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve the treatment landscape for mental health conditions through its proprietary NSAs. More information can be found at www.helus.com.
